Alex Matter

Alex Matter (* around 1940) is a Swiss doctor. He is best known for his contributions to the development, testing and approval of the protein kinase inhibitors Imatinib (trade name Glivec) and Nilotinib (trade name Tasigna) and the HIV protease inhibitor Atazanavir (trade name Reyataz).

Matter studied medicine at the University of Basel and the University of Geneva . He received his doctorate in 1966 at the Institute for Pathology at the University of Basel with the thesis electron microscopic examination of the transition point between cardiac muscle fibers and tendons in the papillary muscle of the mammalian heart . He has worked as a postdoctoral fellow in Switzerland, Great Britain , France and the United States . He conducted research for the Swiss National Science Foundation and the Swiss Academy of Medical Sciences . He held a professorship at the medical faculty of the University of Basel and the Eucor . He has published over 100 scientific publications and several book chapters in the field of oncology and hematology .

Matter worked for Hoffmann-La Roche , Schering-Plow and Ciba-Geigy and Novartis for many years , including as head of global oncology research at Novartis. From 2003 to 2009 he was founding director of the Novartis Institute for Tropical Diseases . In 2006 he was a member of the Senate of the Swiss Academy of Medical Sciences . He has been CEO of the Experimental Therapeutics Center since 2009 and of the D3 platform of the Agency for Science, Technology and Research (A * STAR) in Singapore since 2012 .

Awards (selection)

• 2000 Warren Alpert Foundation Prize
• 2002 AACR Bruce F. Cain Memorial Award from the American Association for Cancer Research
• 2013 Szent-Györgyi Prize of the National Foundation for Cancer Research
• Member of the Swiss Academy of Medical Sciences , member of the American Association for Cancer Research

Web links

• Alex Matter at the Experimental Therapeutics Center of the Agency for Science, Technology and Research (a-star.edu.sg)
• CV at A * STAR Chemistry Symposium
• Alex Matter at prabook.com
• Alex Matter's career stations at Interpharma (interpharma.ch)
• Alex Matter on Bloomberg LP (bloomberg.com)

Individual evidence

1. ^ Graham Dutfield: Who Invented Glivec? Does It Matter Anyway? In: Economic and Political Weekly . tape 48 , no. 32 , August 10, 2013, p. 41-42 ( academia.edu ).
2. ↑ DNB 570884756
3. ↑ Senate of the SAMS: Individual members since 1992. (PDF; 101 kB) In: samw.ch. Swiss Academy of Medical Sciences , accessed on January 12, 2019 . 
4. ↑ 2000 Recipients: Alex Matter. In: warrenalpert.org. Warren Alpert Foundation, accessed January 12, 2019 . 
5. ^ AACR Bruce F. Cain Memorial Award Recipients. In: aacr.org. American Association for Cancer Research , accessed January 12, 2019 . 
6. ↑ 2013 Prize: Alex Matter, MD In: nfcr.org. National Foundation for Cancer Research, accessed January 12, 2019 .